ASO Author Reflections: Induction Systemic Chemotherapy for Peritoneal Metastasis of Gastric Cancer

  • Hiroshi OkabeEmail author
ASO Author Reflections



Hiroshi Okabe has no conflicts of interest to disclose.


  1. 1.
    Fujitani K, Yang HK, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17:309–318.CrossRefGoogle Scholar
  2. 2.
    Ishigami H, Fujiwara Y, Fukushima R, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018;36:1922–1929.CrossRefGoogle Scholar
  3. 3.
    Okabe H, Ueda S, Obama K, et al. Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination. Ann Surg Oncol. 2009;16:3227–3236.CrossRefGoogle Scholar
  4. 4.
    Okabe H, Hata H, Hosogi H, et al. A phase 2 study of induction chemotherapy using docetaxel, cisplatin, and S-1 for gastric cancer with peritoneal metastasis (KUGC06). Ann Surg Oncol. 2019;26:1779–1786.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  1. 1.Department of Surgery, Graduate School of MedicineKyoto UniversityKyotoJapan
  2. 2.Department of Gastroenterological SurgeryNew Tokyo HospitalMatsudoJapan

Personalised recommendations